Financhill
Back

Eli Lilly and Quote, Financials, Valuation and Earnings

Eli Lilly and Price Quote

$768.11
+0.35 (+1.4%)
(Updated: December 21, 2024 at 5:35 AM ET)

Eli Lilly and Key Stats

Sell
37
Eli Lilly and (LLY) is a Sell

Day range:
$766.61 - $811.35
52-week range:
$567.42 - $972.53
Dividend yield:
0.68%
P/E ratio:
132.37
P/S ratio:
16.99
P/B ratio:
51.18%

Volume:
9.4M
Avg. volume:
4.3M
1-year change:
34.65%
Market cap:
$728.8B
Revenue:
$34.1B
EPS:
$9.25

How Much Does Eli Lilly and Make?

Data Unavailable

Is Eli Lilly and Growing As A Company?

Data Unavailable

Eli Lilly and Stock Price Performance

  • Did Eli Lilly and Stock Go Up Last Month?
    Eli Lilly and share price went up by 1.9% last month
  • Did LLY's Share Price Rise Over The Last Year?
    LLY share price rose by 34.65% over the past 1 year

What Is Eli Lilly and 52-Week High & Low?

Eli Lilly and Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Eli Lilly and?

Data Unavailable

Is Eli Lilly and Cash Flow Positive?

Data Unavailable

Eli Lilly and Return On Invested Capital

Data Unavailable

Eli Lilly and Earnings Date & Stock Price

  • What Is Eli Lilly and's Stock Price Today?
    A single share of LLY can be purchased today for 767.76
  • What Is Eli Lilly and’s Stock Symbol?
    Eli Lilly and trades on the S&P500 under the ticker symbol: LLY
  • When Is Eli Lilly and’s Next Earnings Date?
    The next quarterly earnings date for Eli Lilly and is scheduled on May 1, 2025
  • When Is LLY's next ex-dividend date?
    Eli Lilly and's next ex-dividend date is February 14, 2025
  • How To Buy Eli Lilly and Stock?
    You can buy Eli Lilly and shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

Eli Lilly and Competitors

  • Who Are Eli Lilly and's Competitors?
    Below is a list of companies who compete with Eli Lilly and or are related in some way:
    • Amgen Inc (AMGN)
    • Biogen Inc (BIIB)
    • Moderna Inc (MRNA)
    • Regeneron Pharmaceuticals Inc (REGN)
    • Viking Therapeutics Inc (VKTX)

Eli Lilly and Dividend Yield

Data Unavailable

Eli Lilly and Analyst Estimates

YoY Growth Past Surprise
EPS: 68.21% -19.52%
Revenue: 20.43% -5.61%

Analyst Recommendations

Buy Recommendations: 15
Hold Recommendations: 6
Sell Recommendations: 0
Price Target: 984.05
Upside from Last Price: 28.17%

Major Shareholders

Data Unavailable